Zura Bio (ZURA)

• Market cap: $98.5M
• 1 day: 10.79%
• 5 days: 6.94%
• 1 month: 19.38%
• 3 months: -12.50%
• 6 months: -66.74%
• Year to date: -34.47%
• 1 year: -63.93%
• 5 years: -78.73%
• 10 years: -78.73%
• Sector: Healthcare
• Industry: Biotechnology

About: Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Employees: 30

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

220% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 10

79% more call options, than puts

Call options by funds: $522K | Put options by funds: $291K

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

10% more funds holding

Funds holding: 78 [Q3] → 86 (+8) [Q4]

7.31% more ownership

Funds ownership: 58.38% [Q3] → 65.69% (+7.31%) [Q4]

29% less capital invested

Capital invested by funds: $151M [Q3] → $107M (-$43.9M) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 95% upside
• Avg. target: $11.75 663% upside
• High target: $19 1,134% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 58 / 188 met price target	95% upside $3	Neutral Maintained	3 Apr 2025
Oppenheimer Jeff Jones 6% 1-year accuracy 2 / 33 met price target	1,134% upside $19	Outperform Maintained	26 Mar 2025
Guggenheim Yatin Suneja 24% 1-year accuracy 8 / 33 met price target	874% upside $15	Buy Reiterated	26 Mar 2025
Chardan Capital Matthew Barcus 0% 1-year accuracy 0 / 2 met price target	549% upside $10	Buy Maintained	26 Mar 2025